絞り込み

16633

広告

Characterizing the Morbidity of Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients.

著者 Macleod LC , Rajanahally S , Nayak JG , Parent BA , Ramos JD , Schade GR , Holt SK , Dash A , Gore JL , Lin DW
Urology.2016 Jan 20 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (7view , 0users)

Full Text Sources

Medical

To characterize morbidity of post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for testis cancer we analyze a contemporary national database. PC-RPLND is the standard for residual radiographic masses ≥ 1 cm (non-seminoma) and PET-avid masses ≥ 3 cm (seminoma). Morbidity for PC-RPLND is greater than primary RPLND, which may be mitigated by performing surgery at a high volume cancer center.
PMID: 26802801 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード